术前血小板与淋巴细胞比值是Ⅱ期结直肠癌患者的一个预后标志物。
The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer.
作者信息
Ozawa Tsuyoshi, Ishihara Soichiro, Nishikawa Takeshi, Tanaka Toshiaki, Tanaka Junichiro, Kiyomatsu Tomomichi, Hata Keisuke, Kawai Kazushige, Nozawa Hiroaki, Kazama Shinsuke, Yamaguchi Hironori, Sunami Eiji, Kitayama Joji, Watanabe Toshiaki
机构信息
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo, 113-8655, Japan,
出版信息
Int J Colorectal Dis. 2015 Sep;30(9):1165-71. doi: 10.1007/s00384-015-2276-9. Epub 2015 Jun 7.
PURPOSE
The platelet to lymphocyte ratio (PLR) is a potential prognostic marker in a number of different cancers. The aim of this study was to evaluate the prognostic impact of the PLR in patients with stage II colorectal cancer (CRC) who have undergone curative resection but not adjuvant chemotherapy.
METHODS
A retrospective review was performed on 234 patients with stage II CRC who underwent curative resection, but not adjuvant chemotherapy, in our institute. The patients were divided into low and high PLR groups, and patient survival as well as several clinicopathological factors were compared between the groups. Disease-free survival (DFS) and cancer-specific survival (CSS) were analyzed by using the Kaplan-Meier method, and multivariate analysis was performed by using the Cox proportional hazard model.
RESULTS
The cutoff value of the PLR determined by using a receiver-operating characteristic curve analysis was 25.4. DFS and CSS were significantly better in patients with a low PLR compared to patients with a high PLR (P = 0.002 and P = 0.011, respectively). On multivariate analysis, we identified the PLR as an independent prognostic factor for DFS and CSS, with a hazard ratio of 2.65 (95 % confidence interval [CI], 1.26-5.45; P = 0.011) and 3.61 (95 % CI, 1.08-12.64; P = 0.038, respectively).
CONCLUSIONS
The PLR is a good prognostic indicator in patients with stage II CRC who have undergone curative surgery but not adjuvant chemotherapy.
目的
血小板与淋巴细胞比值（PLR）在多种不同癌症中是一种潜在的预后标志物。本研究的目的是评估PLR对接受根治性切除但未接受辅助化疗的II期结直肠癌（CRC）患者的预后影响。
方法
对我院234例接受根治性切除但未接受辅助化疗的II期CRC患者进行回顾性研究。将患者分为PLR低分组和高分组，比较两组患者的生存情况以及一些临床病理因素。采用Kaplan-Meier法分析无病生存期（DFS）和癌症特异性生存期（CSS），并使用Cox比例风险模型进行多因素分析。
结果
通过受试者工作特征曲线分析确定的PLR临界值为25.4。与PLR高的患者相比，PLR低的患者DFS和CSS明显更好（分别为P = 0.002和P = 0.011）。多因素分析显示，PLR是DFS和CSS的独立预后因素，风险比分别为2.65（95%置信区间[CI]，1.26 - 5.45；P = 0.011）和3.61（95% CI，1.08 - 12.64；P = 0.038）。
结论
PLR是接受根治性手术但未接受辅助化疗的II期CRC患者的良好预后指标。
Zotero 插件